Aldeyra Therapeutics, Inc. (ALDX) saw its loss widen to $18.70 million, or $1.65 a share for the year ended Dec. 31, 2016. In the previous year period, the company reported a loss of $12.09 million, or $1.40 a share.
The company has not recorded any revenues for the current as well as previous year.
Operating loss for the year was $18.70 million, compared with an operating loss of $11.99 million in the previous year.
"2016 was a productive year for Aldeyra, highlighted by positive data from our late-stage clinical programs in allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome," commented Todd C. Brady, M.D., Ph.D., president and chief executive officer of Aldeyra. "We look forward to building upon our accomplishments from last year as we advance our clinical programs, two of which are expected to commence Phase 3 studies in 2017. In addition, we expect to initiate a new clinical program in Dry Eye Syndrome."
Working capital declines
Aldeyra Therapeutics, Inc. has witnessed a decline in the working capital over the last year. It stood at $22.83 million as at Dec. 31, 2016, down 12.09 percent or $3.14 million from $25.97 million on Dec. 31, 2015. Current ratio was at 10.93 as on Dec. 31, 2016, down from 13.28 on Dec. 31, 2015.
Debt moves up marginally
Aldeyra Therapeutics, Inc. has witnessed an increase in total debt over the last one year. It stood at $1.32 million as on Dec. 31, 2016, up 2.12 percent or $0.03 million from $1.29 million on Dec. 31, 2015. Total debt was 5.23 percent of total assets as on Dec. 31, 2016, compared with 4.57 percent on Dec. 31, 2015. Debt to equity ratio was almost stable at 0.06 as on Dec. 31, 2016, when compared with the last year.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
